Sandoz Group (OTCMKTS:SDZNY) Upgraded by Barclays to “Strong-Buy” Rating

Sandoz Group (OTCMKTS:SDZNY) was upgraded by investment analysts at Barclays from a “hold” rating to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

Several other research firms also recently weighed in on SDZNY. The Goldman Sachs Group raised Sandoz Group to a “strong-buy” rating in a research report on Wednesday, April 1st. Royal Bank Of Canada downgraded Sandoz Group from a “moderate buy” rating to a “hold” rating in a research report on Monday, March 23rd. Finally, Jefferies Financial Group raised Sandoz Group from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 12th. Three equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Strong Buy”.

Sandoz Group Price Performance

OTCMKTS SDZNY opened at $84.29 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 1.18 and a debt-to-equity ratio of 0.53. The stock has a 50-day moving average of $81.61 and a two-hundred day moving average of $76.13. Sandoz Group has a 1-year low of $44.02 and a 1-year high of $94.15.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.